Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Change in Cash: 2009-2025

Historic Change in Cash for Aytu Biopharma (AYTU) over the last 17 years, with Sep 2025 value amounting to $1.7 million.

  • Aytu Biopharma's Change in Cash rose 1545.10% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.5 million, marking a year-over-year increase of 8595.83%. This contributed to the annual value of $10.9 million for FY2025, which is 467.44% up from last year.
  • As of Q3 2025, Aytu Biopharma's Change in Cash stood at $1.7 million, which was down 86.87% from $12.8 million recorded in Q2 2025.
  • Over the past 5 years, Aytu Biopharma's Change in Cash peaked at $12.8 million during Q2 2025, and registered a low of -$15.5 million during Q1 2021.
  • In the last 3 years, Aytu Biopharma's Change in Cash had a median value of $231,000 in 2024 and averaged $1.2 million.
  • Within the past 5 years, the most significant YoY rise in Aytu Biopharma's Change in Cash was 5,094.72% (2025), while the steepest drop was 1,063.20% (2025).
  • Quarterly analysis of 5 years shows Aytu Biopharma's Change in Cash stood at -$5.3 million in 2021, then grew by 18.42% to -$4.3 million in 2022, then soared by 89.91% to -$435,000 in 2023, then surged by 166.67% to $290,000 in 2024, then soared by 1,545.10% to $1.7 million in 2025.
  • Its Change in Cash stands at $1.7 million for Q3 2025, versus $12.8 million for Q2 2025 and -$2.2 million for Q1 2025.